VINC Vincerx Pharma Inc
Price (delayed)
$0.63
Market cap
$3.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$15.85
Enterprise value
-$1.77M
Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs
Highlights
The debt has plunged by 100% from the previous quarter and by 100% YoY
VINC's EPS has soared by 58% year-on-year and by 23% since the previous quarter
The company's net income rose by 25% YoY but it fell by 11% QoQ
The company's equity has shrunk by 76% YoY and by 70% QoQ
The quick ratio has dropped by 53% year-on-year and by 51% since the previous quarter
Key stats
What are the main financial stats of VINC
Market
Valuations
Earnings
Shares outstanding
5.23M
Market cap
$3.3M
Enterprise value
-$1.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.39
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.46M
Net income
-$30.07M
EBIT
-$30.07M
EBITDA
-$28.98M
Free cash flow
-$26.13M
Per share
Balance sheet
Liquidity
EPS
-$15.85
EPS diluted
-$15.85
Free cash flow per share
-$13.77
Book value per share
$1.62
Revenue per share
$0
TBVPS
$4.22
Total assets
$8.01M
Total liabilities
$5.28M
Debt
$0
Equity
$2.72M
Working capital
$1.13M
Debt to equity
0
Current ratio
1.21
Quick ratio
1.16
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-216.5%
Return on equity
-451.3%
Return on invested capital
-898.3%
Return on capital employed
-1,104%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VINC stock price
How has the Vincerx Pharma stock price performed over time
Intraday
9.57%
1 week
4.55%
1 month
-42.2%
1 year
-99.51%
YTD
-88.02%
QTD
19%
Financial performance
How have Vincerx Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.46M
Net income
-$30.07M
Gross margin
N/A
Net margin
N/A
VINC's operating income is up by 26% year-on-year but it is down by 12% since the previous quarter
The company's net income rose by 25% YoY but it fell by 11% QoQ
Growth
What is Vincerx Pharma's growth rate over time
Valuation
What is Vincerx Pharma stock price valuation
P/E
N/A
P/B
0.39
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VINC's EPS has soared by 58% year-on-year and by 23% since the previous quarter
The stock's P/B is 92% below its 5-year quarterly average of 4.3
The company's equity has shrunk by 76% YoY and by 70% QoQ
Efficiency
How efficient is Vincerx Pharma business performance
VINC's return on equity has dropped by 140% year-on-year and by 47% since the previous quarter
The ROA has plunged by 71% YoY and by 32% from the previous quarter
Vincerx Pharma's return on invested capital has decreased by 49% QoQ
Dividends
What is VINC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VINC.
Financial health
How did Vincerx Pharma financials performed over time
The total assets is 52% more than the total liabilities
The total assets has plunged by 56% YoY and by 46% from the previous quarter
VINC's current ratio has dropped by 54% year-on-year and by 44% since the previous quarter
The debt is 100% less than the equity
The debt has plunged by 100% from the previous quarter and by 100% YoY
VINC's debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.